Skip to main content
Clinical Trials/NCT00207077
NCT00207077
Completed
Phase 1

A Phase I Study of Cetuximab in Combination With Erlotinib in Patients With Advanced Solid Malignancies

Eli Lilly and Company1 site in 1 country33 target enrollmentAugust 2005

Overview

Phase
Phase 1
Intervention
Cetuximab + Erlotinib
Conditions
Neoplasms
Sponsor
Eli Lilly and Company
Enrollment
33
Locations
1
Primary Endpoint
Safety and efficacy of the combination of Tarceva and Erbitux
Status
Completed
Last Updated
10 years ago

Overview

Brief Summary

The purpose of this study is to find a safe and effective dose of the combination of cetuximab (Erbitux) and Tarceva (erlotinib).

Registry
clinicaltrials.gov
Start Date
August 2005
End Date
May 2007
Last Updated
10 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Measurable disease
  • Life expectancy of at least 3 months
  • Must have at least one prior chemotherapy containing a platinum

Exclusion Criteria

  • Known or documented brain metastases
  • Prior cetuximab therapy

Arms & Interventions

A

Intervention: Cetuximab + Erlotinib

Outcomes

Primary Outcomes

Safety and efficacy of the combination of Tarceva and Erbitux

Secondary Outcomes

  • Radiographic response

Study Sites (1)

Loading locations...

Similar Trials